(UroToday.com) The Society of Urologic Oncology (SUO) annual winter meeting included a bladder cancer session and a presentation by Dr. Michael Creswell discussing the economic outcomes of hexaminolevulinate blue-light cystoscopy compared to white light cystoscopy for the diagnosis and monitoring of non-muscle invasive bladder cancer (NMIBC). Bladder cancer is the sixth most common cancer in the United States, with NMIBC representing 70% of new bladder cancer diagnoses. Due to high recurrence rates and health system utilization, bladder cancer is among the most expensive cancers to treat on a per-patient basis. Historically, TURBT was performed with white light cystoscopy, however, blue light cystoscopy with hexaminolevulinate has gained favor over white light cystoscopy due to improved detection of clinically significant neoplastic lesions.1 Despite the higher upfront cost of blue light cystoscopy, improved diagnostic accuracy, and surveillance of NMIBC may yield long-term cost savings and decreased financial burden on healthcare systems.2 This study sought to model American Urologic Association (AUA) bladder cancer guidelines and run a Monte Carlo simulation to investigate the 5-year cost comparison of blue light cystoscopy and white light cystoscopy.